Covalon Technologies Gains Board Member With Experience in Non-Profit, Public, Private Sectors

Covalon Technologies Ltd., an advanced medical technologies company, has appointed Ron Smith to its Board of Directors. Smith will chair the board’s Audit Committee.
 
Smith (FCPA, FCA, ICD.D) is an experienced independent director with years of board experience in the private, not-for-profit, and public sectors. He is the board chairman of the Nova Scotia Public Service Superannuation Fund and of the Western Regional Enterprise Network. He also serves on the boards of Alamos Gold Inc., PROREIT, the IWK Health Centre, Ombudsman for Banking Services and Investments (OBSI), and Engage Nova Scotia. Over his career, Smith has held numerous high-profile executive positions. He served as interim CEO of Nova Scotia Business Inc. concurrently with his work as a director thereof. He was chief financial officer (CFO) of Nova Scotia Power and Emera prior to his retirement in 2005, and CFO of MT&T prior to the merger that created Bell Aliant. He has also served on the Canada Pension Plan Investment Board, was chair of the Board of Governors of Acadia University from 2004 to 2009, and chaired the National Board of The Arthritis Society from 2016 to 2018. Smith is a Fellow of the Chartered Professional Accountants and holds the ICD.D designation from the Rotman School of Business.
 
“I am deeply honored to serve on Covalon’s Board and Audit Committee,” said Smith. “I am impressed with Covalon’s growth over the course of its history, and its recent acquisition and lucrative contracts. I look forward to contributing to Covalon’s continued success.”
 
“I am thrilled to have Mr. Smith join our Board and Audit Committee,” said Brian Pedlar, CEO. “Mr. Smith’s vast experience in finance, directorships, and executive leadership would be extremely valuable on any board, and we are certain that his insights and experience will be a major contribution to Covalon’s continued success.”
 
Smith’s appointment to Covalon’s Board of Directors is subject to TSX approval.

Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon’s patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon’s technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings.